Annabelle Mahar
Overview
Explore the profile of Annabelle Mahar including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
52
Citations
719
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Murphy G, Shatz J, Bonar S, Mahar A, Boyle R
ANZ J Surg
. 2024 May;
94(7-8):1409-1411.
PMID: 38727028
No abstract available.
2.
Harrison M, Jo H, Troy L, Nguyen B, Webster S, Geis M, et al.
Respir Med
. 2024 Feb;
224:107533.
PMID: 38355019
Background And Objective: The interstitial lung diseases (ILD) are a heterogenous group of disorders with similar clinical presentation, but widely varying prognoses. The use of a pragmatic disease behaviour classification...
3.
Bovee J, Webster F, Amary F, Baumhoer D, Bloem J, Bridge J, et al.
Histopathology
. 2022 Dec;
82(4):531-540.
PMID: 36464647
Background And Objectives: Bone tumours are relatively rare and, as a consequence, treatment in a centre with expertise is required. Current treatment guidelines also recommend review by a specialised pathologist....
4.
Connolly E, Bhadri V, Wake J, Ingley K, Lewin J, Bae S, et al.
Cancer Med
. 2022 Feb;
11(8):1805-1816.
PMID: 35178869
Methods: A multi-centre retrospective cohort study of patients diagnosed between 2014-2019. Results: Eighteen patients were identified. The median age was 27 years (range 13-56), 10 patients were male (56%), 11...
5.
Fielder T, Butler J, Tierney G, Holmes M, Lam K, Satgunaseelan L, et al.
Pathology
. 2021 Oct;
54(4):399-403.
PMID: 34702583
A small subset of lung adenocarcinomas harbour ROS1 gene arrangements and are amenable to tyrosine kinase inhibitor therapy. Current practice in Australia involves screening for ROS1 rearrangements in adenocarcinomas using...
6.
Cooper W, Mahar A, Myers J, Grainge C, Corte T, Williamson J, et al.
Arch Pathol Lab Med
. 2021 Oct;
145(11):1326-1327.
PMID: 34673907
No abstract available.
7.
Ahmadzada T, Cooper W, Holmes M, Mahar A, Westman H, Gill A, et al.
JTO Clin Res Rep
. 2021 Sep;
1(4):100075.
PMID: 34589956
Introduction: We investigated the efficacy and toxicity of pembrolizumab in patients with mesothelioma from a real-world Australian population. We aimed to determine clinical factors and predictive biomarkers that could help...
8.
Potter A, Dimitriou F, Karim R, Mahar A, Chan C, Long G, et al.
Pathology
. 2021 Aug;
54(3):369-371.
PMID: 34420793
No abstract available.
9.
Hulme K, Robbins E, Crawford M, Mahar A, McKenzie C
Pathology
. 2021 Jul;
54(1):140-143.
PMID: 34215446
No abstract available.
10.
Paver E, OToole S, Cheng X, Mahar A, Cooper W
Semin Diagn Pathol
. 2021 May;
38(5):54-61.
PMID: 33985831
An understanding of the molecular pathology of non-small cell lung cancer (NSCLC) is important for pathologists as molecular characterization is now required for treatment decisions in advanced stage disease. While...